Insulet Corp

Insulet insider buying shows executive confidence: EVP Panos Michael’s April 2026 purchase signals optimism amid a 16.8% monthly decline, hinting at future upside despite high P/E and regulatory risks.

Insulet CEO Ashley McEvoy buys 4,300 shares, signaling confidence as the company expands its insulin platform and seeks growth in Canada and the UK.

Insulet insider trades show routine vesting, not volatility—executives buy and sell shares near current price, signaling confidence and steady growth prospects.